Botox for chronic tension headaches: read the evidence separately from migraine
BOTOX’s chronic migraine indication does not cover chronic tension-type headache. Placebo-controlled tension-headache trials measured their own headache outcomes.
BOTOX is FDA approved for prevention of headaches in adults with chronic migraine, not for chronic tension-type headache. Placebo-controlled trials in chronic tension-type headache did not establish a benefit on their primary headache outcomes. A clinician needs to identify the headache disorder before applying a migraine indication, even if the pain feels like tension or involves the neck.1234
What the clinician needs to identify
“Tension headache” is often a description of how pain feels. Chronic tension-type headache is a defined diagnosis. The International Headache Society classification distinguishes that disorder from other headaches and addresses situations in which headache patterns can coexist. Explain what you feel and what else happens with it, rather than trying to decide which label the symptoms meet. A tight neck or a report of head pressure alone does not put a person in the FDA’s chronic migraine population.14
This also changes the consultation you are arranging. A practice may list cosmetic neuromodulator services or migraine treatment without evaluating a separate tension-type headache diagnosis. Treomark’s migraine versus cosmetic Botox guide explains those two service paths. This decision comes before either one: what kind of headache is being treated, and what change would count as success?14
Read the primary measure before a secondary finding
One multicenter placebo-controlled study enrolled 300 people. Its primary comparison was change in monthly days free of tension-type headache. None of the toxin groups showed superiority on that measure; placebo performed better than one active group on the primary comparison. Some groups showed a response on a later secondary measure. A result from that secondary measure is not a substitute for the trial’s main test of efficacy.2
Another randomized study evaluated a different botulinum toxin type A product in 112 people and excluded people with coexisting migraine. It did not find a significant difference on its primary headache diary comparison. That study and the larger study support a narrow conclusion about their tested treatment and outcomes, not an estimate of what every product would do for every individual.3
| A claim about | What to verify |
|---|---|
| Chronic migraine | The clinician’s diagnosis, current product label and intended preventive outcome. |
| Tension-type pain | Whether the study enrolled this diagnosis and what its primary measure showed. |
| A later response | Whether it was the main trial outcome or a secondary observation. |
| Cosmetic care | Whether the practice evaluates headaches or only lists cosmetic treatment. |
What a secondary signal can and cannot add
A trial can find a difference on one of several measures even when the main comparison does not establish efficacy. That observation can justify asking a new research question. It does not automatically change the FDA indication or give the same result in a clinic that is using a different product, examining a different headache pattern or recording a different outcome. If a practice cites the later response, ask it to identify the primary result as well and to explain what it would measure in your case. The two original trials and the product label give you separate records to compare.123
Find the right clinician for the question
Bring a record of the headache pattern and prior diagnoses to a clinician who evaluates headaches. Ask which diagnosis the proposal addresses and which outcome the clinician would follow. An injectables listing describes advertised services. It does not establish that the practice can diagnose or treat the headache you are experiencing.14
If you have difficulty swallowing, speaking or breathing after a botulinum toxin injection, seek immediate medical attention. That is a separate safety handoff from evaluating a recurring headache pattern.1
Sources
- DailyMed / BOTOX prescribing information. BOTOX (onabotulinumtoxinA) prescribing information. Lists the chronic migraine indication, distinct approved uses and symptoms for immediate medical attention after toxin. Accessed .
- Cephalalgia / original randomized trial. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Original public abstract describes 300 enrolled and the primary headache-free-days comparison. Accessed .
- Pain / original randomized trial. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Public abstract describes a separate toxin product, excluding coexisting migraine, and no benefit on the primary headache measure. Accessed .
- International Headache Society. 2.3 Chronic tension-type headache. Diagnostic classification distinguishes tension-type headache from other headache disorders. Accessed .